Why Agilent Is Spending up to $270 Million on an AI Pathology Specialist
Agilent (A) to acquire Proscia for up to $270M to expand AI-powered digital pathology & diagnostic capabilities. Stock edges higher.
Stocks · News reference
Morgan Stanley Maintains Overweight on Agilent Technologies, Raises Price Target to $190
Morgan Stanley analyst Kallum Titchmarsh maintains Agilent Technologies (NYSE:A) with a Overweight and raises the price target from $175 to $190.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
TD Cowen Maintains Buy on Agilent Technologies, Raises Price Target to $196
TD Cowen analyst Dan Brennan maintains Agilent Technologies (NYSE:A) with a Buy and raises the price target from $180 to $196.
Agilent Announces Deal To Acquire Digital Pathology Software Firm Proscia For $240M Cash, Up To $30M In Milestones